RG
BMRN icon

Redmile Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Redmile Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100,000
Closed -$8.56M – 76
2019
Q2 		$8.56M Buy
+100,000
New +$8.55M 0.24% 60

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Redmile Group's BMRN Position: Q1 2026 in Review

Redmile Group opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 173,859 shares worth $9.82M. The stake represents 0.65% of the portfolio and ranks #23 among its holdings. This is a return to the name: Redmile Group previously reported a position in BMRN as recently as Q2 2023.

Redmile Group first reported a position in BMRN in Q2 2014 and has held it in 12 quarters since. The position peaked at $42.4M in Q2 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Redmile Group held 173,859 shares of BioMarin Pharmaceuticals worth $9.82M as of Q1 2026.
  • BioMarin Pharmaceuticals was a new Redmile Group position in Q1 2026.
  • BioMarin Pharmaceuticals made up 0.65% of Redmile Group's portfolio in Q1 2026, its #23 holding.
  • Redmile Group first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 12 quarters since.
  • Redmile Group's BioMarin Pharmaceuticals position peaked at $42.4M in Q2 2023.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.